|
|
|
|
| LEADER |
01818nam a2200361 u 4500 |
| 001 |
EB002001638 |
| 003 |
EBX01000000000000001164539 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Poitras, Veronica
|
| 245 |
0 |
0 |
|a Guanfacine hydrochloride extended-release for the treatment of attention deficit hyperactivity disorder in adults
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Veronica Poitras, Suzanne McCormack
|
| 246 |
3 |
1 |
|a Guanfacine hydrochloride extended-release for the treatment of ADHD in adults
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c 2018, September 11, 2018
|
| 300 |
|
|
|a 1 PDF file (19 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Attention Deficit Disorder with Hyperactivity / drug therapy
|
| 653 |
|
|
|a Guanfacine / economics
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Guanfacine / standards
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Guanfacine / therapeutic use
|
| 653 |
|
|
|a Delayed-Action Preparations
|
| 700 |
1 |
|
|a McCormack, Suzanne
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK537958
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a The purpose of this report is to examine the clinical effectiveness, cost-effectiveness, and evidence-based guidelines regarding the use of guanfacine hydrochloride extended-release for the treatment of adults with attention deficit hyperactivity disorder (ADHD)
|